Albino Sonaly Lima, da Silva Moura Willian Charles, Reis Malu Maria Lucas Dos, Sousa Gleyton Leonel Silva, da Silva Pablo Rayff, de Oliveira Mayara Gabriele Carvalho, Borges Tatiana Karla Dos Santos, Albuquerque Lucas Fraga Friaça, de Almeida Sinara Mônica Vitalino, de Lima Maria do Carmo Alves, Kuckelhaus Selma Aparecida Souza, Nascimento Igor José Dos Santos, Junior Francisco Jaime Bezerra Mendonca, da Silva Teresinha Gonçalves, de Moura Ricardo Olímpio
Programa de Pós Graduação em Inovação Terapêutica, Universidade Federal de Pernambuco, Recife 50670-901, Brazil.
Laboratório de Desenvolvimento e Síntese de Fármacos, Departamento de Farmácia, Universidade Estadual da Paraíba, Campina Grande 58429-500, Brazil.
Pharmaceuticals (Basel). 2023 Jan 29;16(2):204. doi: 10.3390/ph16020204.
The present study proposed the synthesis of a novel acridine derivative not yet described in the literature, chemical characterization by NMR, MS, and IR, followed by investigations of its antileishmanial potential. In vitro assays were performed to assess its antileishmanial activity against strains and cytotoxicity against macrophages through MTT assay and annexin V-FITC/PI, and the ability to perform an immunomodulatory action using CBA. To investigate possible molecular targets, its interaction with DNA in vitro and in silico targets were evaluated. As results, the compound showed good antileishmanial activity, with IC of 6.57 (amastigotes) and 94.97 (promastigotes) µg mL, associated with non-cytotoxicity to macrophages (CC > 256.00 µg mL). When assessed by flow cytometry, 99.8% of macrophages remained viable. The compound induced an antileishmanial effect in infected macrophages and altered TNF-α, IL-10 and IL-6 expression, suggesting a slight immunomodulatory activity. DNA assay showed an interaction with the minor grooves due to the hyperchromic effect of 47.53% and Kb 1.17 × 10 M, and was sustained by docking studies. Molecular dynamics simulations and MM-PBSA calculations propose cysteine protease B as a possible target. Therefore, this study demonstrates that the new compound is a promising molecule and contributes as a model for future works.
本研究提出合成一种文献中尚未描述的新型吖啶衍生物,通过核磁共振(NMR)、质谱(MS)和红外光谱(IR)进行化学表征,随后研究其抗利什曼原虫的潜力。进行了体外试验,通过MTT试验和膜联蛋白V-异硫氰酸荧光素/碘化丙啶(annexin V-FITC/PI)评估其对菌株的抗利什曼原虫活性和对巨噬细胞的细胞毒性,并使用细胞因子珠阵列(CBA)评估其免疫调节作用的能力。为了研究可能的分子靶点,评估了其在体外与DNA的相互作用以及计算机模拟靶点。结果显示,该化合物具有良好的抗利什曼原虫活性,对无鞭毛体的半数抑制浓度(IC)为6.57 μg/mL,对前鞭毛体的IC为94.97 μg/mL,且对巨噬细胞无细胞毒性(半数细胞毒性浓度CC>256.00 μg/mL)。通过流式细胞术评估,99.8%的巨噬细胞仍保持活力。该化合物在感染的巨噬细胞中诱导了抗利什曼原虫作用,并改变了肿瘤坏死因子-α(TNF-α)、白细胞介素-10(IL-10)和白细胞介素-6(IL-6)的表达,表明具有轻微的免疫调节活性。DNA试验显示由于47.53%的增色效应和1.17×10⁻⁶ M的结合常数(Kb),该化合物与小沟相互作用,对接研究也证实了这一点。分子动力学模拟和分子力学-泊松-玻尔兹曼表面积计算(MM-PBSA)表明半胱氨酸蛋白酶B可能是一个靶点。因此,本研究表明该新化合物是一个有前景的分子,并为未来的研究提供了一个模型。